Janus Henderson Horizon Biotechnology Fund

A2 USD ISIN code: LU1897414303

Ratings and awards

Investment objective

The Biotechnology Fund aims to provide capital growth. The Fund invests at least 80% of its net assets in equities and equity-related instruments of biotechnology and biotechnology-related companies worldwide. “Biotechnology and biotechnology-related companies” is defined as: • companies that are included in the NASDAQ Biotechnology Index; • companies that develop small molecule or biologic drugs subject to the approval of global regulatory agencies; • companies that market products or services to aid in the research and development of small molecule or biologic drugs; or • companies that are considered such by the Investment Manager. In choosing investments, the Investment Manager aims to select biotechnology companies that he or she believes to be undervalued, with greater potential for clinical and/or commercial success than is currently reflected in market prices. The Fund may invest in companies of any size, including smaller capitalisation companies. Equity-related instruments may include depository receipts and derivative instruments (such as futures, forwards, equity swaps (also known as contract-for-differences), swaps and options and warrants). The Fund may use derivative instruments for investment purposes (up to 10% of its net assets) and hedging purposes. The underlyings consist of a range of securities or indices that the Fund may invest in according to the Fund’s investment objective and policy, The Investment Manager may from time to time consider hedging currency and interest rates exposure, but will not generally enter into contracts involving a speculative position in any currency or interest rate. On an ancillary basis and for defensive purposes, the Fund may invest in: • convertible bonds and associated derivative instruments; • cash, money market instruments or derivative instruments that are used to provide downside market protection or dampen market volatility.

Overview

The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.

Potential investors must read the prospectus, and where relevant, the key investor information document before investing.

This website is for financial promotion purposes and is not investment advice.

Before you invest

Share class:

Key documents

All documents
ISIN code: LU1897414303A2 USD Currency USD NAV 10.5800 Change 0.7600% Price date 20/09/2019
 
ISIN code: LU1897414485H2 USD Currency USD NAV 10.6200 Change 0.6600% Price date 20/09/2019
Performance

Past performance is not a guide to future performance. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.

Discrete performance

Due to financial regulations we are only permitted to show fund performance over a minimum period of one year.

Cumulative performance

Due to financial regulations we are only permitted to show fund performance over a minimum period of one year.
Top 10 holdings
Geographic breakdown
Sector breakdown
Dividends
Key data
Asset class Equities
Structure SICAV
Launch date 10/12/2018
Base currency USD
Sector Morningstar Europe OE Equity Biotechnology
Benchmark NASDAQ Biotechnology Total Return Index
Year end 30-Jun
Valuation point 16:00
Pricing basis Single Priced

A2 USD

Distribution type Accumulation Net
ISIN code LU1897414303
WKN Code A2N85V
Valoren Code 44961707
Initial charge 5.00%
Annual charges 1.20%
Launch date 10/12/2018
Currency USD
Performance FeeCertain classes within a fund may be able to charge a performance related management fee, which becomes payable when that class outperforms its performance fee benchmark and previous high watermark (where applicable).An indication of the historic performance fee payable can be found in the relevant KIID.20% of the 'Relevant Amount'
Minimum Lump Sum USD2,500.00
Additional lump sum investment USD500.00

H2 USD

Distribution type Accumulation Net
ISIN code LU1897414485
WKN Code A2N85W
Valoren Code 44961728
Initial charge 5.00%
Annual charges 0.75%
Launch date 10/12/2018
Currency USD
Performance FeeCertain classes within a fund may be able to charge a performance related management fee, which becomes payable when that class outperforms its performance fee benchmark and previous high watermark (where applicable).An indication of the historic performance fee payable can be found in the relevant KIID.20% of the 'Relevant Amount'
Minimum Lump Sum USD750,000.00
Additional lump sum investment USD2,500.00
General risks
  • ​The value of the Funds and the income from them is not guaranteed and may fall as well as rise. You may get back less than you originally invested.
  • ​Past performance is not a guide to future performance.
  • ​For detailed product information including the risks associated with investing please read the relevant Prospectus or Annual Report.
  • Before investing in any of our funds you should satisfy yourself as to the suitability and the risks involved, you may wish to consult a financial adviser.
  • Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.
Specific risks
  • The Fund could lose money if a counterparty with which it trades becomes unwilling or unable to meet its obligations to the Fund.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • Changes in currency exchange rates may cause the value of your investment and any income from it to rise or fall.
  • If the Fund or a specific share class of the Fund seeks to reduce risks (such as exchange rate movements), the measures designed to do so may be ineffective, unavailable or detrimental.
  • The Fund's value may fall where it has concentrated exposure to a particular industry that is heavily affected by an adverse event.
  • Any security could become hard to value or to sell at a desired time and price, increasing the risk of investment losses.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.

Announcements

Important message